1		Roche
2		ROCEPHIN®
3		(ceftriaxone sodium)
4		FOR INJECTION
~	Dy anh	

5 Rx only

6 To reduce the development of drug-resistant bacteria and maintain the effectiveness of

7 Rocephin and other antibacterial drugs, Rocephin should be used only to treat or prevent

8 infections that are proven or strongly suspected to be caused by bacteria.

9 **DESCRIPTION**

10 Rocephin is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for 11 intravenous or intramuscular administration. Ceftriaxone sodium is (6R,7R)-7-[2-(2-


12 Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-

13 triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7^2 -(Z)-

14 (*O*-methyloxime), disodium salt, sesquaterhydrate.

15 The chemical formula of ceftriaxone sodium is $C_{18}H_{16}N_8Na_2O_7S_3\bullet 3.5H_2O$. It has a

16 calculated molecular weight of 661.59 and the following structural formula:



17

18 Rocephin is a white to yellowish-orange crystalline powder which is readily soluble in

19 water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1%

20 aqueous solution is approximately 6.7. The color of Rocephin solutions ranges from light

21 yellow to amber, depending on the length of storage, concentration and diluent used.

Rocephin contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone
 activity.

24 CLINICAL PHARMACOLOGY

Average plasma concentrations of ceftriaxone following a single 30-minute intravenous (IV) infusion of a 0.5, 1 or 2 gm dose and intramuscular (IM) administration of a single

27 0.5 (250 mg/mL or 350 mg/mL concentrations) or 1 gm dose in healthy subjects are

28 presented in Table 1.

29 30

Table 1Ceftriaxone Plasma Concentrations After Single Dose
Administration

Dose/Route		Average Plasma Concentrations (µg/mL)							
	0.5 hr	1 hr	2 hr	4 hr	6 hr	8 hr	12 hr	16 hr	24 hr
0.5 gm IV*	82	59	48	37	29	23	15	10	5
0.5 gm IM									
250 mg/mL	22	33	38	35	30	26	16	ND	5
0.5 gm IM									
350 mg/mL	20	32	38	34	31	24	16	ND	5
1 gm IV*	151	111	88	67	53	43	28	18	9
1 gm IM	40	68	76	68	56	44	29	ND	ND
2 gm IV*	257	192	154	117	89	74	46	31	15

31 *IV doses were infused at a constant rate over 30 minutes.

32 ND = Not determined.

Ceftriaxone was completely absorbed following IM administration with mean maximum plasma concentrations occurring between 2 and 3 hours postdosing. Multiple IV or IM doses ranging from 0.5 to 2 gm at 12- to 24-hour intervals resulted in 15% to 36%

36 accumulation of ceftriaxone above single dose values.

37 Ceftriaxone concentrations in urine are high, as shown in Table 2.

Table 2 Urinary Concentrations of Ceftriaxone After Single Dose Administration

Dose/Route	Average Urinary Concentrations (µg/mL)					
	0-2 hr	2-4 hr	4-8 hr	8-12 hr	12-24 hr	24-48 hr
0.5 gm IV	526	366	142	87	70	15
0.5 gm IM	115	425	308	127	96	28
1 gm IV	995	855	293	147	132	32
1 gm IM	504	628	418	237	ND	ND
2 gm IV	2692	1976	757	274	198	40

40 ND = Not determined.

Thirty-three percent to 67% of a ceftriaxone dose was excreted in the urine as unchanged drug and the remainder was secreted in the bile and ultimately found in the feces as microbiologically inactive compounds. After a 1 gm IV dose, average concentrations of ceftriaxone, determined from 1 to 3 hours after dosing, were 581 μ g/mL in the gallbladder bile, 788 μ g/mL in the common duct bile, 898 μ g/mL in the cystic duct bile, 78.2 μ g/gm in the gallbladder wall and 62.1 μ g/mL in the concurrent plasma.

47 Over a 0.15 to 3 gm dose range in healthy adult subjects, the values of elimination half-48 life ranged from 5.8 to 8.7 hours; apparent volume of distribution from 5.78 to 13.5 L; 49 plasma clearance from 0.58 to 1.45 L/hour; and renal clearance from 0.32 to 0.73 L/hour. 50 Ceftriaxone is reversibly bound to human plasma proteins, and the binding decreased 51 from a value of 95% bound at plasma concentrations of <25 μ g/mL to a value of 85% 52 bound at 300 μ g/mL. Ceftriaxone crosses the blood placenta barrier.

53 The average values of maximum plasma concentration, elimination half-life, plasma 54 clearance and volume of distribution after a 50 mg/kg IV dose and after a 75 mg/kg IV 55 dose in pediatric patients suffering from bacterial meningitis are shown in Table 3. 56 Ceftriaxone penetrated the inflamed meninges of infants and pediatric patients; CSF 57 concentrations after a 50 mg/kg IV dose and after a 75 mg/kg IV dose are also shown in 58 Table 3.

59	Table 3	Average Pharmacokinetic Parameters of Ceftriaxone in
60		Pediatric Patients With Meningitis

	50 mg/kg IV	75 mg/kg IV
Maximum Plasma Concentrations (µg/mL)	216	275
Elimination Half-life (hr)	4.6	4.3
Plasma Clearance (mL/hr/kg)	49	60
Volume of Distribution (mL/kg)	338	373
CSF Concentration—inflamed meninges (µg/mL)	5.6	6.4
Range (µg/mL)	1.3-18.5	1.3-44
Time after dose (hr)	3.7 (± 1.6)	3.3 (± 1.4)

61 Compared to that in healthy adult subjects, the pharmacokinetics of ceftriaxone were only 62 minimally altered in elderly subjects and in patients with renal impairment or hepatic 63 dysfunction (Table 4); therefore, dosage adjustments are not necessary for these patients with ceftriaxone dosages up to 2 gm per day. Ceftriaxone was not removed to any 64 65 significant extent from the plasma by hemodialysis. In 6 of 26 dialysis patients, the elimination rate of ceftriaxone was markedly reduced, suggesting that plasma 66 67 concentrations of ceftriaxone should be monitored in these patients to determine if dosage 68 adjustments are necessary.

69Table 4Average Pharmacokinetic Parameters of Ceftriaxone in70Humans

Subject Group	Elimination	Plasma	Volume of
	Half-Life	Clearance	Distribution
	(hr)	(L/hr)	(L)
Healthy Subjects	5.8-8.7	0.58-1.45	5.8-13.5
Elderly Subjects (mean age, 70.5 yr)	8.9	0.83	10.7
Patients With Renal Impairment			
Hemodialysis Patients (0-5 mL/min)*	14.7	0.65	13.7
Severe (5-15 mL/min)	15.7	0.56	12.5
Moderate (16-30 mL/min)	11.4	0.72	11.8
Mild (31-60 mL/min)	12.4	0.70	13.3
Patients With Liver Disease	8.8	1.1	13.6

71 *Creatinine clearance.

72 Pharmacokinetics in the Middle Ear Fluid: In one study, total ceftriaxone 73 concentrations (bound and unbound) were measured in middle ear fluid obtained during 74 the insertion of tympanostomy tubes in 42 pediatric patients with otitis media. Sampling 75 times were from 1 to 50 hours after a single intramuscular injection of 50 mg/kg of

76 ceftriaxone. Mean (\pm SD) ceftriaxone levels in the middle ear reached a peak of 35 (\pm 12)

 μ g/mL at 24 hours, and remained at 19 (± 7) μ g/mL at 48 hours. Based on middle ear

- 78 fluid ceftriaxone concentrations in the 23 to 25 hour and the 46 to 50 hour sampling time
- 79 intervals, a half-life of 25 hours was calculated. Ceftriaxone is highly bound to plasma
- 80 proteins. The extent of binding to proteins in the middle ear fluid is unknown.
- 81 *Microbiology:* The bactericidal activity of ceftriaxone results from inhibition of cell wall 82 synthesis. Ceftriaxone has a high degree of stability in the presence of beta-lactamases,
- 83 both penicillinases and cephalosporinases, of gram-negative and gram-positive bacteria.
- 84 In an *in vitro* study antagonistic effects have been observed with the combination of 85 chloramphenicol and ceftriaxone.
- 86 Ceftriaxone has been shown to be active against most strains of the following
- microorganisms, both in vitro and in clinical infections described in the INDICATIONS
 AND USAGE section.
- 89 Aerobic gram-negative microorganisms:
- 90 Acinetobacter calcoaceticus
- 91 Enterobacter aerogenes
- 92 Enterobacter cloacae
- 93 Escherichia coli
- 94 *Haemophilus influenzae* (including ampicillin-resistant and beta-lactamase producing
- 95 strains)
- 96 Haemophilus parainfluenzae
- 97 Klebsiella oxytoca
- 98 Klebsiella pneumoniae
- 99 Moraxella catarrhalis (including beta-lactamase producing strains)
- 100 Morganella morganii
- 101 *Neisseria gonorrhoeae* (including penicillinase- and nonpenicillinase-producing strains)
- 102 Neisseria meningitidis
- 103 Proteus mirabilis
- 104 Proteus vulgaris
- 105 Serratia marcescens
- 106 Ceftriaxone is also active against many strains of *Pseudomonas aeruginosa*.
- 107 NOTE: Many strains of the above organisms that are multiply resistant to other 108 antibiotics, eg, penicillins, cephalosporins, and aminoglycosides, are susceptible to
- 109 ceftriaxone.
- 110 Aerobic gram-positive microorganisms:
- 111 Staphylococcus aureus (including penicillinase-producing strains)
- 112 Staphylococcus epidermidis
- 113 Streptococcus pneumoniae
- 114 Streptococcus pyogenes
- 115 Viridans group streptococci

- 116 NOTE: Methicillin-resistant staphylococci are resistant to cephalosporins, including
- 117 ceftriaxone. Most strains of Group D streptococci and enterococci, eg, Enterococcus
- 118 (*Streptococcus*) faecalis, are resistant.
- 119 Anaerobic microorganisms:
- 120 Bacteroides fragilis
- 121 Clostridium species
- 122 Peptostreptococcus species
- 123 NOTE: Most strains of *Clostridium difficile* are resistant.
- 124 The following in vitro data are available, **but their clinical significance is unknown**.
- 125 Ceftriaxone exhibits in vitro minimal inhibitory concentrations (MICs) of $\leq 8 \mu g/mL$ or
- 126 less against most strains of the following microorganisms, however, the safety and
- 127 effectiveness of ceftriaxone in treating clinical infections due to these microorganisms
- 128 have not been established in adequate and well-controlled clinical trials.
- 129 Aerobic gram-negative microorganisms:
- 130 Citrobacter diversus
- 131 Citrobacter freundii
- 132 Providencia species (including Providencia rettgeri)
- 133 Salmonella species (including Salmonella typhi)
- 134 Shigella species
- 135 Aerobic gram-positive microorganisms:
- 136 *Streptococcus agalactiae*
- 137 Anaerobic microorganisms:
- 138 Prevotella (Bacteroides) bivius
- 139 Porphyromonas (Bacteroides) melaninogenicus

140 **Susceptibility Tests:**

141 Dilution Techniques: Quantitative methods are used to determine antimicrobial minimal 142 inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of 143 bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure.¹ Standardized procedures are based on a dilution method (broth 144 145 or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ceftriaxone powder. The MIC values should be interpreted according to 146 the following criteria² for aerobic organisms other than *Haemophilus* spp. *Neisseria* 147 148 gonorrhoeae, and Streptococcus spp, including Streptococcus pneumoniae:

<u>MIC (μg/mL)</u>	Interpretation
≤ 8	(S) Susceptible
16-32	(I) Intermediate
≥64	(R) Resistant
2	

149 The following interpretive criteria² should be used when testing *Haemophilus* species 150 using Haemophilus Test Media (HTM).

MIC ($\mu g/mL$)

Interpretation

≤2

(S) Susceptible

151 The absence of resistant strains precludes defining any categories other than 152 "Susceptible". Strains yielding results suggestive of a "Nonsusceptible" category should

153 be submitted to a reference laboratory for further testing.

154 The following interpretive criteria² should be used when testing *Neisseria gonorrhoeae* 155 when using GC agar base and 1% defined growth supplement.

MIC (µg/mL)	<u>Interpretation</u>
≤0.25	(S) Susceptible

The absence of resistant strains precludes defining any categories other than
"Susceptible". Strains yielding results suggestive of a "Nonsusceptible" category should
be submitted to a reference laboratory for further testing.

159 The following interpretive criteria² should be used when testing *Streptococcus* spp

160 including *Streptococcus pneumoniae* using cation-adjusted Mueller-Hinton broth with 2161 to 5% lysed horse blood.

MIC (µg/mL)	Interpretation
≤0.5	(S) Susceptible
1	(I) Intermediate
>2	(R) Resistant

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the 162 163 antimicrobial compound in the blood reaches the concentrations usually achievable. A 164 report of "Intermediate" indicates that the results should be considered equivocal, and if 165 the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites 166 167 where the drug is physiologically concentrated or in situations where high dosage of the drug can be used. This category also provides a buffer zone which prevents small 168 169 uncontrolled technical factors from causing major discrepancies in interpretation. A 170 report of "Resistant" indicates that the pathogen is not likely to be inhibited if the 171 antimicrobial compound in the blood reaches the concentrations usually achievable; other 172 therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control
microorganisms to control the technical aspects of the laboratory procedures.
Standardized ceftriaxone powder should provide the following MIC values:²

Microorganism	ATCC [®] #	MIC (µg/mL)
Escherichia coli	25922	0.03 - 0.12
Staphylococcus aureus	29213	1 - 8*
Pseudomonas aeruginosa	27853	8 - 32
Haemophilus influenzae	49247	0.06 - 0.25
Neisseria gonorrhoeae	49226	0.004 - 0.015
Streptococcus pneumoniae	49619	0.03 - 0.12

* A bimodal distribution of MICs results at the extremes of the acceptable range should be suspect and control validity should be verified with data from other control strains.

178 **Diffusion Techniques:** Quantitative methods that require measurement of zone 179 diameters also provide reproducible estimates of the susceptibility of bacteria to 180 antimicrobial compounds. One such standardized procedure³ requires the use of 181 standardized inoculum concentrations. This procedure uses paper discs impregnated with 182 $30 \mu g$ of ceftriaxone to test the susceptibility of microorganisms to ceftriaxone.

183 Reports from the laboratory providing results of the standard single-disc susceptibility 184 test with a 30 µg ceftriaxone disc should be interpreted according to the following criteria 185 for aerobic organisms other than *Haemophilus* spp, *Neisseria gonorrhoeae*, and 186 *Streptococcus* spp:

Zone Diameter (mm)	Interpretation
≥21	(S) Susceptible
14-20	(I) Intermediate
≤13	(R) Resistant

187 The following interpretive criteria³ should be used when testing *Haemophilus* species 188 when using Haemophilus Test Media (HTM).

Zone Diameter (mm)	Interpretation
≥26	(S) Susceptible

The absence of resistant strains precludes defining any categories other than
"Susceptible". Strains yielding results suggestive of a "Nonsusceptible" category should
be submitted to a reference laboratory for further testing.

The following interpretive criteria³ should be used when testing *Neisseria gonorrhoeae*when using GC agar base and 1% defined growth supplement.

Zone Diameter (mm)	Interpretation
≥35	(S) Susceptible

194 The absence of resistant strains precludes defining any categories other than 195 "Susceptible". Strains yielding results suggestive of a "Nonsusceptible" category should 196 be submitted to a reference laboratory for further testing.

197 The following interpretive criteria³ should be used when testing *Streptococcus* spp other

198 than *Streptococcus pneumoniae* when using Mueller-Hinton agar supplemented with 5%

199 sheep blood incubated in 5% CO₂.

Zone Diameter (mm)	Interpretation
≥27	(S) Susceptible
25-26	(I) Intermediate
≤24	(R) Resistant

Interpretation should be as stated above for results using dilution techniques.
 Interpretation involves correlation of the diameter obtained in the disc test with the MIC
 for ceftriaxone.

203 Disc diffusion interpretive criteria for ceftriaxone discs against *Streptococcus* 204 *pneumoniae* are not available, however, isolates of pneumococci with oxacillin zone 205 diameters of >20 mm are susceptible (MIC $\leq 0.06 \ \mu g/mL$) to penicillin and can be 206 considered susceptible to ceftriaxone. *Streptococcus pneumoniae* isolates should not be 207 reported as penicillin (ceftriaxone) resistant or intermediate based solely on an oxacillin 208 zone diameter of ≤ 19 mm. The ceftriaxone MIC should be determined for those isolates 209 with oxacillin zone diameters ≤ 19 mm.

210 As with standardized dilution techniques, diffusion methods require the use of laboratory

211 control microorganisms that are used to control the technical aspects of the laboratory

212 procedures. For the diffusion technique, the 30 µg ceftriaxone disc should provide the

213 following zone diameters in these laboratory test quality control strains:³

Microorganism	ATCC [®] #	Zone Diameter Ranges (mm)
Escherichia coli	25922	29 - 35
Staphylococcus aureus	25923	22 - 28
Pseudomonas aeruginosa	27853	17 - 23
Haemophilus influenzae	49247	31 - 39
Neisseria gonorrhoeae	49226	39 - 51
Streptococcus pneumoniae	49619	30 - 35

214 Anaerobic Techniques: For anaerobic bacteria, the susceptibility to ceftriaxone as MICs

can be determined by standardized test methods.⁴ The MIC values obtained should be interpreted according to the following criteria:

MIC (µg/mL)	Interpretation	
≤16	(S) Susceptible	
32	(I) Intermediate	
≥64	(R) Resistant	

217 As with other susceptibility techniques, the use of laboratory control microorganisms is

required to control the technical aspects of the laboratory standardized procedures.
 Standardized ceftriaxone powder should provide the following MIC values for the
 indicated standardized anaerobic dilution⁴ testing method:

8

Method	<u>Microorganism</u>	ATCC [®] #	<u>MIC (µg/mL)</u>
Agar	Bacteroides fragilis	25285	32 - 128
-	Bacteroides thetaiotaomicron	29741	64 - 256
Broth	Bacteroides thetaiotaomicron	29741	32 - 128
$\wedge \mathbf{TCC}^{\mathbb{R}}$ is a maximum	ristand the domants of the American Type	Culture Collectio	

221 ATCC[®] is a registered trademark of the American Type Culture Collection.

222 INDICATIONS AND USAGE

Before instituting treatment with Rocephin, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug.

225 Therapy may be instituted prior to obtaining results of susceptibility testing.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Rocephin and other antibacterial drugs, Rocephin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Rocephin is indicated for the treatment of the following infections when caused bysusceptible organisms:

235 LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae,

236 Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae,

237 Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or
238 Serratia marcescens.

ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae,
 Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella
 catarrhalis (including beta-lactamase producing strains).

NOTE: In one study lower clinical cure rates were observed with a single dose of
Rocephin compared to 10 days of oral therapy. In a second study comparable cure rates
were observed between single dose Rocephin and the comparator. The potentially lower
clinical cure rate of Rocephin should be balanced against the potential advantages of
parenteral therapy (see CLINICAL STUDIES).

SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus,
Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci,
Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae,
Proteus mirabilis, Morganella morganii,* Pseudomonas aeruginosa, Serratia
marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus
species.

URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by
 Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella
 pneumoniae.

UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria
 gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and
 pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria
 gonorrhoeae.

260 PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Rocephin, like 261 other cephalosporins, has no activity against *Chlamydia trachomatis*. Therefore, when 262 cephalosporins are used in the treatment of patients with pelvic inflammatory disease and 263 *Chlamydia trachomatis* is one of the suspected pathogens, appropriate antichlamydial 264 coverage should be added.

265 BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus 266 pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae.

BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus
 pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter
 species.

INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae,
 Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are
 resistant) or Peptostreptococcus species.

MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or
 Streptococcus pneumoniae. Rocephin has also been used successfully in a limited number
 of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and
 Escherichia coli.*

*Efficacy for this organism in this organ system was studied in fewer than ten infections.

278 SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 gm dose of 279 Rocephin may reduce the incidence of postoperative infections in patients undergoing 280 surgical procedures classified as contaminated or potentially contaminated (eg, vaginal or 281 abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-282 risk patients, such as those over 70 years of age, with acute cholecystitis not requiring 283 therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in 284 surgical patients for whom infection at the operative site would present serious risk (eg, 285 during coronary artery bypass surgery). Although Rocephin has been shown to have been 286 as effective as cefazolin in the prevention of infection following coronary artery bypass 287 surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin 288 antibiotic in the prevention of infection following coronary artery bypass surgery.

When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of Rocephin provides protection from most infections due to susceptible organisms throughout the course of the procedure.

292 **CONTRAINDICATIONS**

Rocephin is contraindicated in patients with known allergy to the cephalosporin class ofantibiotics.

295 **Neonates (\leq 28 days)**

Hyperbilirubinemic neonates, especially prematures, should not be treated with
Rocephin. In vitro studies have shown that ceftriaxone can displace bilirubin from its
binding to serum albumin and bilirubin encephalopathy can possibly develop in these
patients.

300 Rocephin must not be co-administered with calcium-containing IV solutions, 301 including continuous calcium-containing infusions such as parenteral nutrition, in 302 neonates because of the risk of precipitation of ceftriaxone-calcium salt. Cases of 303 fatal reactions with ceftriaxone-calcium precipitates in lung and kidneys in neonates have 304 been described. In some cases the infusion lines and the times of administration of 305 ceftriaxone and calcium-containing solutions differed.

306 For information regarding all other patients, see **WARNINGS**.

307 WARNINGS

308 Hypersensitivity

309 BEFORE THERAPY WITH ROCEPHIN IS INSTITUTED, CAREFUL INQUIRY 310 SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD 311 PREVIOUS HYPERSENSITIVITY REACTIONS ТО CEPHALOSPORINS. PENICILLINS OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN 312 313 CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD 314 BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. 315 SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE THE USE 316 317 OF SUBCUTANEOUS EPINEPHRINE AND OTHER EMERGENCY MEASURES.

318 Interaction with Calcium-Containing Products

319 There are no reports to date of intravascular or pulmonary precipitations in patients, other than neonates, treated with ceftriaxone and calcium-containing IV 320 solutions. However, the theoretical possibility exists for an interaction between 321 322 ceftriaxone and IV calcium-containing solutions in patients other than neonates. 323 Therefore, Rocephin and calcium-containing solutions, including continuous 324 calcium-containing infusions such as parenteral nutrition, should not be mixed or 325 co-administered to any patient irrespective of age, even via different infusion lines at 326 different sites. As a further theoretical consideration and based on 5 half-lives of 327 ceftriaxone, Rocephin and IV calcium-containing solutions should not be 328 administered within **48** hours of each other in any patient (see 329 **CONTRAINDICATIONS and DOSAGE AND ADMINISTRATION).**

330 No data are available on potential interaction between ceftriaxone and oral calcium-

331 containing products or interaction between intramuscular ceftriaxone and calcium-

332 containing products (IV or oral).

333 Clostridium difficile

Clostridium difficile associated diarrhea (CDAD) has been reported with use of
 nearly all antibacterial agents, including Rocephin, and may range in severity from
 mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal
 flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD.
Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as
these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic
use. Careful medical history is necessary since CDAD has been reported to occur over
two months after the administration of antibacterial agents.

344 If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C*.
345 *difficile* may need to be discontinued. Appropriate fluid and electrolyte management,
346 protein supplementation, antibiotic treatment *C. difficile*, and surgical evaluation should
347 be instituted as clinically indicated.

348 **PRECAUTIONS**

General: Prescribing Rocephin in the absence of a proven or strongly suspected bacterial
 infection or a prophylactic indication is unlikely to provide benefit to the patient and
 increases the risk of the development of drug-resistant bacteria.

- Although transient elevations of BUN and serum creatinine have been observed, at the recommended dosages, the nephrotoxic potential of Rocephin is similar to that of other cephalosporins.
- 355 Ceftriaxone is excreted via both biliary and renal excretion (see **CLINICAL** 356 **PHARMACOLOGY**). Therefore, patients with renal failure normally require no 357 adjustment in dosage when usual doses of Rocephin are administered, but concentrations 358 of drug in the serum should be monitored periodically. If evidence of accumulation 359 exists, dosage should be decreased accordingly.
- Dosage adjustments should not be necessary in patients with hepatic dysfunction;
 however, in patients with both hepatic dysfunction and significant renal disease,
 Rocephin dosage should not exceed 2 gm daily without close monitoring of serum
 concentrations.
- Alterations in prothrombin times have occurred rarely in patients treated with Rocephin. Patients with impaired vitamin K synthesis or low vitamin K stores (eg, chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Rocephin treatment. Vitamin K administration (10 mg weekly) may be necessary if the prothrombin time is prolonged before or during therapy.
- Prolonged use of Rocephin may result in overgrowth of nonsusceptible organisms.Careful observation of the patient is essential. If superinfection occurs during therapy,
- 371 appropriate measures should be taken.

372 Rocephin should be prescribed with caution in individuals with a history of 373 gastrointestinal disease, especially colitis.

374 There have been reports of sonographic abnormalities in the gallbladder of patients 375 treated with Rocephin; some of these patients also had symptoms of gallbladder 376 disease. These abnormalities appear on sonography as an echo without acoustical 377 shadowing suggesting sludge or as an echo with acoustical shadowing which may be 378 misinterpreted as gallstones. The chemical nature of the sonographically detected 379 material has been determined to be predominantly a ceftriaxone-calcium salt. The 380 condition appears to be transient and reversible upon discontinuation of Rocephin 381 and institution of conservative management. Therefore, Rocephin should be 382 discontinued in patients who develop signs and symptoms suggestive of gallbladder 383 disease and/or the sonographic findings described above.

Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely
in patients treated with Rocephin. Most patients presented with risk factors for biliary
stasis and biliary sludge (preceding major therapy, severe illness, total parenteral
nutrition). A cofactor role of Rocephin-related biliary precipitation cannot be ruled out.

388 The elimination of Rocephin is not altered by probenecid.

As with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough
 patient history is taken.

391 *Information for Patients:* Patients should be counseled that antibacterial drugs including 392 Rocephin should only be used to treat bacterial infections. They do not treat viral 393 infections (eg, common cold). When Rocephin is prescribed to treat a bacterial infection, 394 patients should be told that although it is common to feel better early in the course of 395 therapy, the medication should be taken exactly as directed. Skipping doses or not 396 completing the full course of therapy may (1) decrease the effectiveness of the immediate 397 treatment and (2) increase the likelihood that bacteria will develop resistance and will not 398 be treatable by Rocephin or other antibacterial drugs in the future.

399 Diarrhea is a common problem caused by antibiotics which usually ends when the 400 antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients 401 can develop watery and bloody stools (with or without stomach cramps and fever) even 402 as late as two or more months after having taken the last dose of the antibiotic. If this 403 occurs, patients should contact their physician as soon as possible.

404 *Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis:* Considering the
 405 maximum duration of treatment and the class of the compound, carcinogenicity studies
 406 with ceftriaxone in animals have not been performed. The maximum duration of animal
 407 toxicity studies was 6 months.

408 *Mutagenesis:* Genetic toxicology tests included the Ames test, a micronucleus test and a 409 test for chromosomal aberrations in human lymphocytes cultured in vitro with 410 ceftriaxone. Ceftriaxone showed no potential for mutagenic activity in these studies.

411 *Impairment of Fertility:* Ceftriaxone produced no impairment of fertility when given 412 intravenously to rats at daily doses up to 586 mg/kg/day, approximately 20 times the

413 recommended clinical dose of 2 gm/day.

414 *Pregnancy: Teratogenic Effects:* Pregnancy Category B. Reproductive studies have been 415 performed in mice and rats at doses up to 20 times the usual human dose and have no 416 evidence of embryotoxicity, fetotoxicity or teratogenicity. In primates, no embryotoxicity 417 or teratogenicity was demonstrated at a dose approximately 3 times the human dose.

- There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
- *Nonteratogenic Effects:* In rats, in the Segment I (fertility and general reproduction) and
 Segment III (perinatal and postnatal) studies with intravenously administered ceftriaxone,
 no adverse effects were noted on various reproductive parameters during gestation and
 lactation, including postnatal growth, functional behavior and reproductive ability of the
 offspring, at doses of 586 mg/kg/day or less.
- 426 *Nursing Mothers:* Low concentrations of ceftriaxone are excreted in human milk.
 427 Caution should be exercised when Rocephin is administered to a nursing woman.

428 **Pediatric Use:** Safety and effectiveness of Rocephin in neonates, infants and pediatric 429 patients have been established for the dosages described in the DOSAGE AND ADMINISTRATION section. In vitro studies have shown that ceftriaxone, like some 430 431 other cephalosporins, can displace bilirubin from serum albumin. Rocephin should not be 432 hyperbilirubinemic administered to neonates, especially prematures (see 433 **CONTRAINDICATIONS**).

434 *Geriatric Use:* Of the total number of subjects in clinical studies of Rocephin, 32% were
435 60 and over. No overall differences in safety or effectiveness were observed between
436 these subjects and younger subjects, and other reported clinical experience has not
437 identified differences in responses between the elderly and younger patients, but greater
438 sensitivity of some older individuals cannot be ruled out.

The pharmacokinetics of ceftriaxone were only minimally altered in geriatric patients
compared to healthy adult subjects and dosage adjustments are not necessary for geriatric
patients with ceftriaxone dosages up to 2 grams per day (see CLINICAL
PHARMACOLOGY).

443 No dosage adjustment is necessary for patients with impairment of renal or hepatic
444 function; however, blood levels should be monitored in patients with severe renal
445 impairment (e.g., dialysis patients) and in patients with both renal and hepatic
446 dysfunctions.

447 **ADVERSE REACTIONS**

448 Rocephin is generally well tolerated. In clinical trials, the following adverse reactions,

- 449 which were considered to be related to Rocephin therapy or of uncertain etiology, were
- 450 observed:

451 LOCAL REACTIONS—pain, inducation and tenderness was 1% overall. Phlebitis was
452 reported in <1% after IV administration. The incidence of warmth, tightness or inducation
453 was 17% (3/17) after IM administration of 350 mg/mL and 5% (1/20) after IM
454 administration of 250 mg/mL.

- 455 *HYPERSENSITIVITY*—rash (1.7%). Less frequently reported (<1%) were pruritus, fever 456 or chills.
- *HEMATOLOGIC*—eosinophilia (6%), thrombocytosis (5.1%) and leukopenia (2.1%).
 Less frequently reported (<1%) were anemia, hemolytic anemia, neutropenia,
 lymphopenia, thrombocytopenia and prolongation of the prothrombin time.
- GASTROINTESTINAL—diarrhea (2.7%). Less frequently reported (<1%) were nausea or
 vomiting, and dysgeusia. The onset of pseudomembranous colitis symptoms may occur
 during or after antibacterial treatment (see WARNINGS).
- 463 *HEPATIC*—elevations of SGOT (3.1%) or SGPT (3.3%). Less frequently reported 464 (<1%) were elevations of alkaline phosphatase and bilirubin.
- *RENAL*—elevations of the BUN (1.2%). Less frequently reported (<1%) were elevations
 of creatinine and the presence of casts in the urine.
- 467 *CENTRAL NERVOUS SYSTEM*—headache or dizziness were reported occasionally 468 (<1%).
- 469 *GENITOURINARY*—moniliasis or vaginitis were reported occasionally (<1%).
- 470 *MISCELLANEOUS*—diaphoresis and flushing were reported occasionally (<1%).

471 Other rarely observed adverse reactions (<0.1%) include abdominal pain,
472 agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis,
473 bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria,
474 hematuria, jaundice, leukocytosis, lymphocytosis, monocytosis, nephrolithiasis,
475 palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum
476 sickness.

477 Cases of fatal reactions with ceftriaxone-calcium precipitates in lung and kidneys in
478 neonates have been described. In some cases the infusion lines and the times of
479 administration of ceftriaxone and calcium-containing solutions differed (see
480 CONTRAINDICATIONS).

- 481 **Postmarketing Experience:** In addition to the adverse reactions reported during clinical
 482 trials, the following adverse experiences have been reported during clinical practice in
 483 patients treated with Rocephin. Data are generally insufficient to allow an estimate of
 484 incidence or to establish causation.
- 485 *GASTROINTESTINAL* stomatitis and glossitis.
- 486 *GENITOURINARY* oliguria.

487 *DERMATOLOGIC* – exanthema, allergic dermatitis, urticaria, edema. As with many
 488 medications, isolated cases of severe cutaneous adverse reactions (erythema multiforme,
 489 Stevens-Johnson syndrome or Lyell's syndrome/toxic epidermal necrolysis) have been
 490 reported.

491 Cephalosporin Class Adverse Reactions

In addition to the adverse reactions listed above which have been observed in patients
treated with ceftriaxone, the following adverse reactions and altered laboratory test
results have been reported for cephalosporin class antibiotics:

- 495 Adverse Reactions: Allergic reactions, drug fever, serum sickness-like reaction, renal
 496 dysfunction, toxic nephropathy, reversible hyperactivity, hypertonia, hepatic dysfunction
 497 including cholestasis, aplastic anemia, hemorrhage, and superinfection.
- Altered Laboratory Tests: Positive direct Coombs' test, false-positive test for urinary
 glucose, and elevated LDH.
- 500 Several cephalosporins have been implicated in triggering seizures, particularly in 501 patients with renal impairment when the dosage was not reduced (see **DOSAGE AND** 502 **ADMINISTRATION**). If seizures associated with drug therapy occur, the drug should
- 503 be discontinued. Anticonvulsant therapy can be given if clinically indicated.

504 **OVERDOSAGE**

505 In the case of overdosage, drug concentration would not be reduced by hemodialysis or 506 peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be 507 symptomatic.

508 DOSAGE AND ADMINISTRATION

509 Rocephin may be administered intravenously or intramuscularly.

510 Do not use diluents containing calcium, such as Ringer's solution or Hartmann's 511 solution, to reconstitute Rocephin. Particulate formation can result. Rocephin and 512 calcium-containing solutions, including continuous calcium-containing infusions 513 such as parenteral nutrition, should not be mixed or co-administered to any patient 514 irrespective of age, even via different infusion lines at different sites (see 515 CONTRAINDICATIONS and WARNINGS).

- 516 *NEONATES:* Hyperbilirubinemic neonates, especially prematures, should not be treated517 with Rocephin (see **CONTRAINDICATIONS**).
- 518 *PEDIATRIC PATIENTS:* For the treatment of skin and skin structure infections, the 519 recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided 520 doses twice a day). The total daily dose should not exceed 2 grams.
- 521 For the treatment of acute bacterial otitis media, a single intramuscular dose of 50 mg/kg
- 522 (not to exceed 1 gram) is recommended (see **INDICATIONS AND USAGE**).

523 For the treatment of serious miscellaneous infections other than meningitis, the 524 recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. 525 The total daily dose should not exceed 2 grams.

526 In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 527 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to 528 exceed 4 grams daily) is recommended. The daily dose may be administered once a day 529 (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 530 days.

- 531 *ADULTS:* The usual adult daily dose is 1 to 2 grams given once a day (or in equally 532 divided doses twice a day) depending on the type and severity of infection. The total 533 daily dose should not exceed 4 grams.
- 534 If *Chlamydia trachomatis* is a suspected pathogen, appropriate antichlamydial coverage 535 should be added, because ceftriaxone sodium has no activity against this organism.

536 For the treatment of uncomplicated gonococcal infections, a single intramuscular dose of 537 250 mg is recommended.

- 538 For preoperative use (surgical prophylaxis), a single dose of 1 gram administered 539 intravenously 1/2 to 2 hours before surgery is recommended.
- 540 Generally, Rocephin therapy should be continued for at least 2 days after the signs and 541 symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in 542 complicated infections, longer therapy may be required.
- 543 When treating infections caused by *Streptococcus pyogenes*, therapy should be continued 544 for at least 10 days.
- 545 No dosage adjustment is necessary for patients with impairment of renal or hepatic 546 function; however, blood levels should be monitored in patients with severe renal 547 impairment (eg, dialysis patients) and in patients with both renal and hepatic 548 dysfunctions.
- 549 *DIRECTIONS FOR USE: Intramuscular Administration:* Reconstitute Rocephin powder 550 with the appropriate diluent (see **COMPATIBILITY AND STABILITY**).
- 551 Inject diluent into vial, shake vial thoroughly to form solution. Withdraw entire contents 552 of vial into syringe to equal total labeled dose.
- After reconstitution, each 1 mL of solution contains approximately 250 mg or 350 mg equivalent of ceftriaxone according to the amount of diluent indicated below. If required, more dilute solutions could be utilized. A 350 mg/mL concentration is not recommended for the 250 mg vial since it may not be possible to withdraw the entire contents.
- As with all intramuscular preparations, Rocephin should be injected well within the body of a relatively large muscle; aspiration helps to avoid unintentional injection into a blood
- 560 vessel.

Vial Dosage Size	Amount of Diluent to be Added		
	<u>250 mg/mL</u>	<u>350 mg/mL</u>	
250 mg	0.9 mL		
500 mg	1.8 mL	1.0 mL	
1 gm	3.6 mL	2.1 mL	
2 gm	7.2 mL	4.2 mL	

561

562 *Intravenous Administration:* Rocephin should be administered intravenously by infusion 563 over a period of 30 minutes. Concentrations between 10 mg/mL and 40 mg/mL are 564 recommended; however, lower concentrations may be used if desired. Reconstitute vials 565 with an appropriate IV diluent (see **COMPATIBILITY AND STABILITY**).

Vial Dosage Size	Amount of Diluent to be Added
250 mg	2.4 mL
500 mg	4.8 mL
1 gm	9.6 mL
2 gm	19.2 mL

566 After reconstitution, each 1 mL of solution contains approximately 100 mg equivalent of 567 ceftriaxone. Withdraw entire contents and dilute to the desired concentration with the 568 appropriate IV diluent.

569 COMPATIBILITY AND STABILITY: Ceftriaxone has been shown to be compatible with 570 Flagyl[®]* IV (metronidazole hydrochloride). The concentration should not exceed 5 to 7.5 mg/mL metronidazole hydrochloride with ceftriaxone 10 mg/mL as an admixture. The 571 572 admixture is stable for 24 hours at room temperature only in 0.9% sodium chloride injection or 5% dextrose in water (D5W). No compatibility studies have been conducted 573 with the Flagyl[®] IV RTU[®] (metronidazole) formulation or using other diluents. 574 575 Metronidazole at concentrations greater than 8 mg/mL will precipitate. Do not refrigerate 576 the admixture as precipitation will occur.

577 Vancomycin, amsacrine, aminoglycosides, and fluconazole are physically incompatible 578 with ceftriaxone in admixtures. When any of these drugs are to be administered 579 concomitantly with ceftriaxone by intermittent intravenous infusion, it is recommended 580 that they be given sequentially, with thorough flushing of the intravenous lines (with one 581 of the compatible fluids) between the administrations.

582 Do not use diluents containing calcium, such as Ringer's solution or Hartmann's 583 solution, to reconstitute Rocephin. Particulate formation can result.

Rocephin solutions should *not* be physically mixed with or piggybacked into solutions containing other antimicrobial drugs or into diluent solutions other than those listed above, due to possible incompatibility (see **WARNINGS**).

587 Rocephin sterile powder should be stored at room temperature—77°F (25°C)—or below 588 and protected from light. After reconstitution, protection from normal light is not 589 necessary. The color of solutions ranges from light yellow to amber, depending on the 590 length of storage, concentration and diluent used.

- 591 Rocephin *intramuscular* solutions remain stable (loss of potency less than 10%) for the
- 592 following time periods:

		Storage		
Diluent	Concentration	Room Temp.	Refrigerated	
	mg/ml	(25°C)	(4°C)	
Sterile Water for Injection	100	2 days	10 days	
	250, 350	24 hours	3 days	
0.9% Sodium Chloride	100	2 days	10 days	
Solution	250, 350	24 hours	3 days	
5% Dextrose Solution	100	2 days	10 days	
	250, 350	24 hours	3 days	
Bacteriostatic Water + 0.9%	100	24 hours	10 days	
Benzyl Alcohol	250, 350	24 hours	3 days	
1% Lidocaine Solution	100	24 hours	10 days	
(without epinephrine)	250, 350	24 hours	3 days	

593 Rocephin intravenous solutions, at concentrations of 10, 20 and 40 mg/mL, remain stable

594 (loss of potency less than 10%) for the following time periods stored in glass or PVC

595 containers:

596 <u>* Registered trademark of G.D. Searle & Co.</u>

		Storage	
Diluent	Room Temp.	Refrigerated	
	(25°C)	(4°C)	
Sterile Water	2 days	10 days	
0.9% Sodium Chloride Solution	2 days	10 days	
5% Dextrose Solution	2 days	10 days	
10% Dextrose Solution	2 days	10 days	
5% Dextrose + 0.9% Sodium Chloride Solution*	2 days	Incompatible	
5% Dextrose + 0.45% Sodium Chloride Solution	2 days	Incompatible	

*Data available for 10 to 40 mg/mL concentrations in this diluent in PVC containers only.

598 The following *intravenous* Rocephin solutions are stable at room temperature (25°C) for 599 24 hours, at concentrations between 10 mg/mL and 40 mg/mL: Sodium Lactate (PVC

600 container), 10% Invert Sugar (glass container), 5% Sodium Bicarbonate (glass container),

601 Freamine III (glass container), Normosol-M in 5% Dextrose (glass and PVC containers),

602 Ionosol-B in 5% Dextrose (glass container), 5% Mannitol (glass container), 10%

603 Mannitol (glass container).

604 After the indicated stability time periods, unused portions of solutions should be 605 discarded.

NOTE: Parenteral drug products should be inspected visually for particulate matterbefore administration.

Rocephin reconstituted with 5% Dextrose or 0.9% Sodium Chloride solution at
concentrations between 10 mg/mL and 40 mg/mL, and then stored in frozen state (-20°C)
in PVC or polyolefin containers, remains stable for 26 weeks.

- 611 Frozen solutions of Rocephin should be thawed at room temperature before use. After
- 612 thawing, unused portions should be discarded. **DO NOT REFREEZE.**

613 ANIMAL PHARMACOLOGY

614 Concretions consisting of the precipitated calcium salt of ceftriaxone have been found in 615 the gallbladder bile of dogs and baboons treated with ceftriaxone.

These appeared as a gritty sediment in dogs that received 100 mg/kg/day for 4 weeks. A similar phenomenon has been observed in baboons but only after a protracted dosing period (6 months) at higher dose levels (335 mg/kg/day or more). The likelihood of this

- 619 occurrence in humans is considered to be low, since ceftriaxone has a greater plasma
- 620 half-life in humans, the calcium salt of ceftriaxone is more soluble in human gallbladder
- bile and the calcium content of human gallbladder bile is relatively low.

622 HOW SUPPLIED

- 623 Rocephin is supplied as a sterile crystalline powder in glass vials. The following 624 packages are available:
- Vials containing 250 mg equivalent of ceftriaxone. Box of 1 (NDC 0004-1962-02) and box of 10 (NDC 0004-1962-01).
- Vials containing 500 mg equivalent of ceftriaxone. Box of 1 (NDC 0004-1963-02) and
 box of 10 (NDC 0004-1963-01).
- Vials containing 1 gm equivalent of ceftriaxone. Box of 1 (NDC 0004-1964-04) and boxof 10 (NDC 0004-1964-01).
- 631 Vials containing 2 gm equivalent of ceftriaxone. Box of 10 (NDC 0004-1965-01).
- Bulk pharmacy containers, containing 10 gm equivalent of ceftriaxone. Box of 1 (NDC 0004-1971-01). NOT FOR DIRECT ADMINISTRATION.
- NOTE: Rocephin sterile powder should be stored at room temperature, 77°F (25°C) or
 below, and protected from light.

636 CLINICAL STUDIES

- 637 Clinical Trials in Pediatric Patients With Acute Bacterial Otitis Media: In two adequate
- and well-controlled US clinical trials a single IM dose of ceftriaxone was compared with
- 639 a 10 day course of oral antibiotic in pediatric patients between the ages of 3 months and 6
- 640 years. The clinical cure rates and statistical outcome appear in the table below:

Study Day	Ceftriaxone	Comparator –	95%	Statistical
	Single Dose	10 Days of	Confidence	Outcome
	-	Oral Therapy	Interval	
Study 1 – US		amoxicillin/clavulanate		
14	74% (220/296)	82% (247/302)	(-14.4%, -0.5%)	Ceftriaxone is lower than control at
28	58% (167/288)	67% (200/297)	(-17.5%, -1.2%)	study day 14 and 28.
Study 2 - US^5		TMP-SMZ		
14	54% (113/210)	60% (124/206)	(-16.4%, 3.6%)	Ceftriaxone is equivalent to
28	35% (73/206)	45% (93/205)	(-19.9%, 0.0%)	control at study day 14 and 28.

Clinical Efficacy in Evaluable Population

641 An open-label bacteriologic study of ceftriaxone without a comparator enrolled 108 642 pediatric patients, 79 of whom had positive baseline cultures for one or more of the 643 common pathogens. The results of this study are tabulated as follows:

644 Weak 2 and 4 Pasteriologic Eradication Pates in the Par Protocol Analysis in the

644 Week 2 and 4 Bacteriologic Eradication Rates in the Per Protocol Analysis in the Roche645 Bacteriologic Study by pathogen:

	Study Day 13-15		Study Day 30+2	
Organism	No. Analyzed	No. Erad. (%)	No. Analyzed	No. Erad. (%)
Streptococcus pneumoniae	38	32 (84)	35	25 (71)
Haemophilus influenzae	33	28 (85)	31	22 (71)
Moraxella catarrhalis	15	12 (80)	15	9 (60)

646 **REFERENCES**

647 648 649 650	1.	National Committee for Clinical Laboratory Standards, <i>Methods for Dilution</i> <i>Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically;</i> Approved Standard-Fifth Edition. NCCLS document M7-A5 (ISBN 1-56238- 309-9). NCCLS, Wayne, PA 19087-1898, 2000.
651 652 653	2.	National Committee for Clinical Laboratory Standards, Supplemental Tables. NCCLS document M100-S10(M7) (ISBN 1-56238-309-9). NCCLS, Wayne, PA 19087-1898, 2000.
654 655 656 657	3.	National Committee for Clinical Laboratory Standards, <i>Performance Standards for Antimicrobial Disk Susceptibility Tests;</i> Approved Standard-Seventh Edition. NCCLS document M2-A7 (ISBN 1-56238-393-0). NCCLS, Wayne, PA 19087-1898, 2000.
658 659 660 661	4.	National Committee for Clinical Laboratory Standards, <i>Methods for</i> <i>Antimicrobial Susceptibility Testing of Anaerobic Bacteria;</i> Approved Standard-Fourth Edition. NCCLS document M11-A4 (ISBN 1-56238-210-1). NCCLS, Wayne, PA 19087-1898, 1997.

- 6625.Barnett ED, Teele DW, Klein JO, et al. Comparison of Ceftriaxone and663Trimethoprim-Sulfamethoxazole for Acute Otitis Media. Pediatrics. Vol. 99,6641007
- 664 No. 1, January 1997.

665



Roche Laboratories Inc. 340 Kingsland Street Nutley, New Jersey 07110-1199

- 666 667
- 668 XXXXXXXX
- 669 Revised: Month / Year
- 670 Copyright © 1998-200X by Roche Laboratories Inc. All rights reserved.